TY - JOUR
T1 - Structural MRI texture analysis for detecting Alzheimer's disease
AU - Silva, Joana
AU - Bispo, Bruno C.
AU - Rodrigues, Pedro M.
N1 - Funding Information:
This work was supported by Fundação para a Ciência e a Tecnologia (FCT), Portugal, through the project UID/50016/2020. Data collection and sharing for this project were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Funding Information:
This work was supported by Fundação para a Ciência e a Tecnologia (FCT), Portugal, through the project UID/50016/2020. Data collection and sharing for this project were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/6
Y1 - 2023/6
N2 - Purpose:: Alzheimer’s disease (AD) has the highest worldwide prevalence of all neurodegenerative disorders, no cure, and low ratios of diagnosis accuracy at its early stage where treatments have some effect and can give some years of life quality to patients. This work aims to develop an automatic method to detect AD in 3 different stages, namely, control (CN), mild-cognitive impairment (MCI), and AD itself, using structural magnetic resonance imaging (sMRI). Methods:: A set of co-occurrence matrix and texture statistical measures (contrast, correlation, energy, homogeneity, entropy, variance, and standard deviation) were extracted from a two-level discrete wavelet transform decomposition of sMRI images. The discriminant capacity of the measures was analyzed and the most discriminant ones were selected to be used as features for feeding classical machine learning (cML) algorithms and a convolution neural network (CNN). Results:: The cML algorithms achieved the following classification accuracies: 93.3% for AD vs CN, 87.7% for AD vs MCI, 88.2% for CN vs MCI, and 75.3% for All vs All. The CNN achieved the following classification accuracies: 82.2% for AD vs CN, 75.4% for AD vs MCI, 83.8% for CN vs MCI, and 64% for All vs All. Conclusion:: In the evaluated cases, cML provided higher discrimination results than CNN. For the All vs All comparison, the proposedmethod surpasses by 4% the discrimination accuracy of the state-of-the-art methods that use structural MRI.
AB - Purpose:: Alzheimer’s disease (AD) has the highest worldwide prevalence of all neurodegenerative disorders, no cure, and low ratios of diagnosis accuracy at its early stage where treatments have some effect and can give some years of life quality to patients. This work aims to develop an automatic method to detect AD in 3 different stages, namely, control (CN), mild-cognitive impairment (MCI), and AD itself, using structural magnetic resonance imaging (sMRI). Methods:: A set of co-occurrence matrix and texture statistical measures (contrast, correlation, energy, homogeneity, entropy, variance, and standard deviation) were extracted from a two-level discrete wavelet transform decomposition of sMRI images. The discriminant capacity of the measures was analyzed and the most discriminant ones were selected to be used as features for feeding classical machine learning (cML) algorithms and a convolution neural network (CNN). Results:: The cML algorithms achieved the following classification accuracies: 93.3% for AD vs CN, 87.7% for AD vs MCI, 88.2% for CN vs MCI, and 75.3% for All vs All. The CNN achieved the following classification accuracies: 82.2% for AD vs CN, 75.4% for AD vs MCI, 83.8% for CN vs MCI, and 64% for All vs All. Conclusion:: In the evaluated cases, cML provided higher discrimination results than CNN. For the All vs All comparison, the proposedmethod surpasses by 4% the discrimination accuracy of the state-of-the-art methods that use structural MRI.
KW - Alzheimer’s disease
KW - Co-occurrence matrix
KW - Early detection
KW - Magnetic resonance imaging
KW - Mild-cognitive impairment
KW - Texture analysis
UR - http://www.scopus.com/inward/record.url?scp=85153790313&partnerID=8YFLogxK
U2 - 10.1007/s40846-023-00787-y
DO - 10.1007/s40846-023-00787-y
M3 - Article
SN - 1609-0985
VL - 43
SP - 227
EP - 238
JO - Journal of Medical and Biological Engineering
JF - Journal of Medical and Biological Engineering
IS - 3
ER -